MARKET

CLLS

CLLS

Cellectis
NASDAQ
4.330
+0.170
+4.09%
Opening 12:38 12/19 EST
OPEN
4.200
PREV CLOSE
4.160
HIGH
4.360
LOW
4.200
VOLUME
15.93K
TURNOVER
--
52 WEEK HIGH
5.48
52 WEEK LOW
1.100
MARKET CAP
313.17M
P/E (TTM)
-24.7146
1D
5D
1M
3M
1Y
5Y
1D
Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This
Seeking Alpha · 1d ago
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Benzinga · 2d ago
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 3d ago
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
TipRanks · 3d ago
Allogene Therapeutics Reports Result for Servier In Arbitration With Cellectis; Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel; Decision Reconfirms Allogene's Expanded Sub-License Covering EU And UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights
Benzinga · 3d ago
Allogene Wins Arbitration, Retains Full Control of Cema-Cel Rights
Reuters · 3d ago
Cellectis Wins Partial Victory in Arbitration Against Servier Over License Agreement
Reuters · 3d ago
CELLECTIS ANNOUNCES ARBITRAL DECISION IN DISPUTE WITH SERVIER
Reuters · 3d ago
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers Cellectis SA (ADR) stock information, including NASDAQ: CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.